在 中文 中使用 心血管风险 的示例及其翻译为 英语
{-}
-
Political
-
Ecclesiastic
-
Programming
年开展了《预防和控制心血管疾病全国方案》，2006年对这一方案进行了更新，从下列基本方面制定了减少心血管风险的目标：.
The National Programme for Prevention and Control of 布拉哈博士评论这些发现，并说：“我们的研究结果表明，勃起功能障碍本身就是心血管风险的有力预测指标。
Dr. Blaha comments on the findings, saying,"Our results reveal that erectile dysfunction is, in and 在做出治疗决定时考虑整体心血管风险.
Taking overall cardiovascular risk into account when making treatment decisions.降低心血管风险的平行社区解决方案.
Parallel community solutions for cardiovascular risk reduction….性别分层Cox模型用于评估心血管风险。
Sex-stratified Cox models were used to assess cardiovascular risk.胆固醇管理可将心血管风险降低25-35％。
Cholesterol management lowers cardiovascular risk by 25-35 percent.地中海式饮食和降低心血管风险的背后是什么？
What's behind Mediterranean diet and lower cardiovascular risk.他们补充说，这种细菌数量的增加可能暗示心血管风险降低。
They add that an increase in the population of this bacterium may thus suggest a lower cardiovascular risk.OCA的使用与血脂水平升高有关，这通常是心血管风险的指标.
Use 几个月的定期运动可能是降低心血管风险的有效方法。
Barely some months 欧洲心血管风险模型是基于SCORE（SystemicCoronaryRiskEstimation）评估系统。
Their 10-year risk for cardiovascular death was determined using the Systematic COronary 并且，进一步降低LDL水平能够进一步降低心血管风险。
It is very likely that a further reduction in LDL will further reduce cardiovascular risk.这两种用途-降低血糖和降低心血管风险-均已获得FDA批准。
Both of those uses- lowering blood glucose and reducing cardiovascular risk- have been approved by the FDA.JUPITER试验也对于用hsCRP测试来作为决定心血管风险的角色提出重要的质疑。
And the JUPITER trial also raised important questions about the role of hsCRP testing for determining cardiovascular risk.随着中国心血管风险的增加，对缓解心血管疾病的策略的兴趣正在不断增加。
As cardiovascular risk increases in China, interest in strategies to mitigate it is growing.使用Procam风险计算器评估心血管风险，该计算器考虑了年龄，性别，家族史，血压和代谢指标.
Cardiovascular 我们发现每个心血管风险因子预测使用不同模式，例如血管用于血压，视盘用于其他预测。
We found that each CV risk factor prediction uses a distinct pattern, such as blood vessels for blood pressure, and optic disc for other predictions.H2阻滞剂包括法莫替丁(PepcidAC)和雷尼替丁(Zantac)，这类药物不会导致心血管风险增加······.
H2 blockers, which include famotidine(Pepcid AC) and ranitidine(Zantac), were not associated with increased cardiovascular risk….FDA担心Stalevo中的恩他卡朋导致了这些心血管风险，因为对照药物中不含此成分。
We were concerned that the entacapone in Stalevo was responsible for these cardiovascular risks because the comparison drugs do not contain this ingredient.对于糖尿病患者来说，心血管风险随着糖尿病发病时间的延长而增加，特别是在胰岛素治疗患者中。
For people with diabetes, cardiovascular risk increases with advanced duration of diabetes, particularly in insulin-treated patients.
